Abstract Library

#3010 International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Pancreatic Neuroendocrine Tumors

Introduction: A prediction model to predict recurrence within 5 years after surgery for nonfunctional pancreatic neuroendocrine tumors (PanNets) was recently published. This model includes WHO tumor grade, lymph node status and perineural invasion as predictors.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Heidsma C, Van Dieren S, Gill A, Engelsman A, Strobel O,

Keywords: Prediction model, recurrence, pancreatic neuroendocrine,

#2185 Nonfunctional Pancreatic Neuroendocrine Tumor (NF PNET) Imaging and Evaluation Using 18F-FDG and 68Ga- DOTANOC-PET/CT: Initial Data of a Prospective Study

Introduction: Predicting aggressive behavior of NF PNET still remains controversial. It is known that lymph node metastases are rare but possible also on small (1-2 cm) NF-PNET. Positive 18F-FDG-PET/CT avidity is associated with poor prognosis in NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kauhanen O

Authors: Majala S, Seppänen H, Kemppainen J, Arola J, Schalin-Jäntti C,

Keywords: pancreatic neuroendocrine tumors, nonfunctional, incidentaloma, positron emission tomography, diagnosis,

#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment

Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,

Keywords: PDR001, immunotherapy, NET,

#1897 Prognosis of Sporadic Resected Small (≤ 2 cm) Nonfunctional Pancreatic Neuroendocrine Neoplasms - A Multi-Institutional Study

Introduction: Malignant potential of sporadic nonmetastatic nonfunctional pancreatic neuroendocrine tumors (sNF-PNET) is difficult to preoperatively predict

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Sébastien G

Authors: Sallinen V, Le Large T, Tieftrunk E, Galeev S, Kovalenko Z,

Keywords: pancreatic NETs,

#1598 The Exploration of the Clinical Value of Plasma CgA in Nonfunctional Gastroenteropancreatic Neuroendocrine Neoplasms

Introduction: Controversies still remain on the clinical value of CgA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Lv Y, Han X, Mao W, Zhou J, Li J,

Keywords: cgA, NF-GEP-NENs, clinical value,